Remogliflozin - Etabonate

​

Remogliflozin Etabonate (“Remo”) is a unique selective sodium glucose co-transporter (SGLT) 2 small molecule inhibitor. Remo has demonstrated robust insulin-independent lowering or HbA1c and weight in patients with type 2 diabetes by inhibiting reabsorption of glucose in the kidney.  After positive results in a phase 3 clinical study, Remo was approved by the Indian DCGI and commercially launched in June 2019 for the treatment of type 2 diabetes in India.  In September 2019, a fixed dose combination of Remo with metformin was approved for commercial sale by the DCGI. Remogliflozin is marketed as Remo and Remozen, and in combination with metformin as Remo-M and Remozen-M by Avolynt collaborator Glenmark Pharmaceuticals.